Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter drugs, and dietary supplements, as well as active pharmaceutical ingredients and finished dosage forms for central nervous system, cardiovascular, anti-retroviral, anti-diabetics, anti-allergies, gastroenterology, antibiotics, dermatology, respiratory, and oncology, as well as specialty generic formulations. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, transdermal patches, inhalers, vaccines, and depot injections. The company also exports its products to approximately 155 countries. It serves multinational companies. The company was founded in 1986 and is headquartered in Hyderabad, India. The ISIN of this stock is INE406A01037.